JP2013532687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532687A5 JP2013532687A5 JP2013521838A JP2013521838A JP2013532687A5 JP 2013532687 A5 JP2013532687 A5 JP 2013532687A5 JP 2013521838 A JP2013521838 A JP 2013521838A JP 2013521838 A JP2013521838 A JP 2013521838A JP 2013532687 A5 JP2013532687 A5 JP 2013532687A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutically acceptable
- bisulfate
- methanesulfonate
- diluents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36933510P | 2010-07-30 | 2010-07-30 | |
| US61/369,335 | 2010-07-30 | ||
| PCT/US2011/044926 WO2012015677A1 (en) | 2010-07-30 | 2011-07-22 | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532687A JP2013532687A (ja) | 2013-08-19 |
| JP2013532687A5 true JP2013532687A5 (https=) | 2014-09-04 |
| JP5738412B2 JP5738412B2 (ja) | 2015-06-24 |
Family
ID=44513148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013521838A Expired - Fee Related JP5738412B2 (ja) | 2010-07-30 | 2011-07-22 | ｃ−ＭＥＴ阻害剤としての６−（１−メチル−１Ｈ−ピラゾール−４−イル）−３−（２−メチル−２Ｈ−インダゾール−５−イルチオ）−［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8268836B2 (https=) |
| EP (1) | EP2598144B1 (https=) |
| JP (1) | JP5738412B2 (https=) |
| KR (1) | KR20130052740A (https=) |
| CN (1) | CN103002898A (https=) |
| AR (1) | AR085183A1 (https=) |
| AU (1) | AU2011282973B2 (https=) |
| BR (1) | BR112013002211A2 (https=) |
| CA (1) | CA2805494A1 (https=) |
| EA (1) | EA201270818A1 (https=) |
| ES (1) | ES2516940T3 (https=) |
| IN (1) | IN2012MN02924A (https=) |
| MX (1) | MX2013001247A (https=) |
| TW (1) | TWI431008B (https=) |
| WO (1) | WO2012015677A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6129956B2 (ja) * | 2012-05-09 | 2017-05-17 | イーライ リリー アンド カンパニー | 抗ｃ−Ｍｅｔ抗体 |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US10386376B2 (en) | 2015-11-09 | 2019-08-20 | Jeimei, Llc | Sample container with integrated test strip |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080584A (ko) * | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CN101558070A (zh) * | 2006-10-23 | 2009-10-14 | Sgx药品公司 | 三唑并哒嗪蛋白激酶调节剂 |
| AU2007309149C1 (en) * | 2006-10-23 | 2013-04-04 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| CA2667453A1 (en) | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Triazolo-pyridazine protein kinase modulators |
| PA8792501A1 (es) * | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
-
2011
- 2011-07-20 AR ARP110102632A patent/AR085183A1/es unknown
- 2011-07-22 EP EP11741372.4A patent/EP2598144B1/en not_active Not-in-force
- 2011-07-22 BR BR112013002211A patent/BR112013002211A2/pt not_active IP Right Cessation
- 2011-07-22 US US13/188,496 patent/US8268836B2/en not_active Expired - Fee Related
- 2011-07-22 AU AU2011282973A patent/AU2011282973B2/en not_active Expired - Fee Related
- 2011-07-22 CA CA2805494A patent/CA2805494A1/en not_active Abandoned
- 2011-07-22 ES ES11741372.4T patent/ES2516940T3/es active Active
- 2011-07-22 MX MX2013001247A patent/MX2013001247A/es not_active Application Discontinuation
- 2011-07-22 CN CN2011800371928A patent/CN103002898A/zh active Pending
- 2011-07-22 TW TW100126076A patent/TWI431008B/zh not_active IP Right Cessation
- 2011-07-22 JP JP2013521838A patent/JP5738412B2/ja not_active Expired - Fee Related
- 2011-07-22 WO PCT/US2011/044926 patent/WO2012015677A1/en not_active Ceased
- 2011-07-22 EA EA201270818A patent/EA201270818A1/ru unknown
- 2011-07-22 KR KR1020137002382A patent/KR20130052740A/ko not_active Ceased
-
2012
- 2012-12-31 IN IN2924MUN2012 patent/IN2012MN02924A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532687A5 (https=) | ||
| NL301201I2 (nl) | Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride | |
| NL301294I2 (nl) | Dasiglucagon of een farmaceutisch aanvaardbaar zout of solvaat daarvan, zoals dasiglucagon hydrochloride | |
| NL301284I2 (nl) | Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine | |
| JP2013532130A5 (https=) | ||
| NL301191I2 (nl) | voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan | |
| JP2012107057A5 (https=) | ||
| JP2011105738A5 (https=) | ||
| NL301243I2 (nl) | Ivosidenib of een farmaceutisch aanvaardbaar zout, tautomeer, isotopoloog of hydraat daarvan | |
| NO2022044I1 (no) | daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid | |
| NL301119I2 (nl) | Selinexor of een farmaceutisch aanvaardbaar zout ervan | |
| NL301256I2 (nl) | cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301047I2 (nl) | fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride | |
| NO2022010I1 (no) | ripretinib, or a pharmaceutically acceptable salt thereof | |
| FIC20240022I1 (fi) | Retsafungiini tai sen farmaseuttisesti hyväksyttävä suola, erityisesti retsafungiiniasetaatti | |
| JP2012111758A5 (https=) | ||
| JP2011168603A5 (https=) | ||
| JP2013032389A5 (https=) | ||
| JP2014507446A5 (https=) | ||
| NL300886I2 (nl) | baricitinib, of een farmaceutisch aanvaardbaar zout daarvan | |
| JP2011510079A5 (https=) | ||
| NL300901I2 (nl) | pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan | |
| JP2013014622A5 (https=) | ||
| JP2013508347A5 (https=) | ||
| JP2011518833A5 (https=) |